Peptide-MHC complexes presenting Epstein-Barr virus EBNA-1 and LMP2 antigens (EBNA1/LMP2 pMHC)

Peptide-MHC (pMHC) complexes presenting Epstein-Barr virus (EBV) EBNA-1 and LMP2 antigens are critical therapeutic targets for EBV-associated malignancies. EBNA-1 (Epstein-Barr nuclear antigen 1) and LMP2 (Latent membrane protein 2) are viral proteins expressed during the latent phase of EBV infection, which is linked to cancers such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD) [2, 4, 21]. Because these proteins are primarily intracellular, they are not accessible to conventional antibodies; however, they are processed into peptides and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules [2, 9, 14]. These pMHC complexes serve as the primary recognition site for the cellular immune system, specifically cytotoxic T lymphocytes (CTLs) via their T-cell receptors (TCRs) [4, 7, 9]. Therapeutic strategies targeting these complexes include adoptive T-cell therapies (e.g., tabelecleucel), TCR-engineered T cells (TCR-T), and TCR-like (or TCR-mimic) antibodies and bispecifics that recognize the specific peptide-HLA configuration [2, 3, 15]. A significant challenge in targeting these complexes is the virus's ability to evade immune detection, such as the EBNA-1 protein's glycine-alanine repeat (GAr) domain which inhibits its own proteasomal degradation and subsequent MHC-I presentation [11, 18]. Clinical development of these therapies often requires patient selection based on specific HLA alleles, most commonly HLA-A*02:01, to ensure the therapeutic agent can recognize the presented viral peptide [2, 4, 15]. Monitoring of EBV DNA load and antigen expression levels serves as a key biomarker for assessing treatment efficacy and disease progression [3, 6].

Other names

EBNA-1/LMP2 peptide-HLA complexesEBV latent antigen pMHC complexesEBNA-1/LMP2 pHLAEBNA-1/LMP2 TCR-like targets

T-cell receptor (TCR) mediated recognition and cytotoxic killing, T-cell redirection via bispecific antibodies, and induction of antigen-specific T-cell immunity through vaccination.